Journal of cancer research and clinical oncology · 2026
Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Sijian, Xian Bingna, Cui Lanyue, Wu Linyu, Fang Cheng, Yang Fan, Li Jundong
Аннотация
PURPOSE: To evaluate the safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer (PROC).
METHODS: We enrolled PROC patients who received intravenous nab-paclitaxel (260 mg/m2), nedaplatin (80 mg/m2), and bevacizumab (10 mg/m2) every 3 weeks between January 1, 2021, and October 1, 2025. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), CA125 response rate, objective response rate (ORR), duration of response (DOR), and safety.
RESULTS: Twenty-seven patients were included (median age 57.8 years; range: 35-78), 16 (59.3%) had received ≥ 3 prior chemotherapy lines; 40.7% and 59.3% had prior bevacizumab and PARP inhibitor exposure, respectively. After a median follow-up of 10 months (range: 3-40), the median PFS was 7.0 months (95% CI 5.8-8.2), with a 2-year OS rate of 57.3%. The CA125 response rate was 81.5%, with a median CA125 reduction of 70.2% (IQR 62.6-93.4), and 48.1% of patients achieved CA125 normalization. Prior chemotherapy lines, bevacizumab/PARP inhibitors exposure, and a shorter platinum-free interval did not alter the therapeutic efficacy (all P > 0.05). Among 12 patients evaluable per RECIST v1.1 criteria, the ORR was 58.3%, the median DOR was 7.0 months (95% CI 4.9-9.0), and the disease control rate was 100%. Grade 3-4 treatment-related adverse events occurred in 10 patients, mostly hematologic toxicities.
CONCLUSION: This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.
METHODS: We enrolled PROC patients who received intravenous nab-paclitaxel (260 mg/m2), nedaplatin (80 mg/m2), and bevacizumab (10 mg/m2) every 3 weeks between January 1, 2021, and October 1, 2025. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), CA125 response rate, objective response rate (ORR), duration of response (DOR), and safety.
RESULTS: Twenty-seven patients were included (median age 57.8 years; range: 35-78), 16 (59.3%) had received ≥ 3 prior chemotherapy lines; 40.7% and 59.3% had prior bevacizumab and PARP inhibitor exposure, respectively. After a median follow-up of 10 months (range: 3-40), the median PFS was 7.0 months (95% CI 5.8-8.2), with a 2-year OS rate of 57.3%. The CA125 response rate was 81.5%, with a median CA125 reduction of 70.2% (IQR 62.6-93.4), and 48.1% of patients achieved CA125 normalization. Prior chemotherapy lines, bevacizumab/PARP inhibitors exposure, and a shorter platinum-free interval did not alter the therapeutic efficacy (all P > 0.05). Among 12 patients evaluable per RECIST v1.1 criteria, the ORR was 58.3%, the median DOR was 7.0 months (95% CI 4.9-9.0), and the disease control rate was 100%. Grade 3-4 treatment-related adverse events occurred in 10 patients, mostly hematologic toxicities.
CONCLUSION: This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.